The relationship of denosumab pharmacology and osteonecrosis of the jaws

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 114, Issue 6, 2012, Pages 671-676

  Malan, John ^a   Ettinger, Kyle ^b   Naumann, Erich ^c   Beirne, O Ross ^d  

^a Dental Corps   (Japan)

^b MAYO CLINIC   (United States)

^c University of Washington ^*

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869420342     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oooo.2012.08.439     Document Type: Article

References (37)

1. G.A. Rodan, A.A. Reszka Bisphosphonate mechanism of action Curr Mol Med 2 2002 571 577
2. N.B. Watts, D.L. Diab Long-term use of bisphosphonates in osteoporosis J Clin Endocrinol Metab 95 2010 1555 1565
3. H. Fleisch Bisphosphonates in osteoporosis Eur Spine J 12 Suppl 2 2003 S142 S146
4. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 2003 1115 1117
5. C.A. Migliorati, S.B. Woo, I. Hewson, A. Barasch, L.S. Elting, F.K. Spijkervet A systematic review of bisphosphonate osteonecrosis (BON) in cancer Support Care Cancer 18 2010 1099 1106
6. S. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, B. Mehrotra American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update J Oral Maxillofac Surg 67 Suppl 1 2009 2 12
7. A. Khan, G.K. Sandor, E. Dore, A.D. Morrison, M. Alsahii, F. Amin Canadian consensus practice guideline for bisphosphonate associated osteonecrosis of the jaw J Rheumatol 7 2008 1391 1397
8. A. Badros, E. Terpos, E. Katodritou, O. Goloubeva, E. Kastritis, E. Verrou Natural history of osteonecrosis of the jaw in patients with multiple myeloma J Clin Oncol 26 2008 5904 5909
9. C.A. Migliorati, J. Casiglia, J. Epstein, P.L. Jacobsen, M.A. Siegel, S.B. Woo Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper J Am Dent Assoc 136 2005 1658 1668
10. R. Vij, N. Horvath, A. Spencer, K. Taylor, S. Vadhan-Raj, R. Vescio An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma Am J Hematol 84 2009 650 658
11. K. Fizazi, L. Bosserman, G. Gao, T. Skacel, R. Markus Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial J Urol 182 2009 509 516
12. D.S. Silver Denosumab reduces the incidence of new vertebral fractures in men with prostate cancer Curr Osteoporos Rep 8 2010 1 3
13. A. Lipton, G.G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.J. Body Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 2007 4431 4437
14. M.B. Bridgeman, R. Pathak Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review Clin Ther 33 2011 1547 1559
15. S. Papapoulos, R. Chapurlat, C. Libanati, M.L. Brandi, J.P. Brown, E. Czerwiski Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension J Bone Miner Res 27 2012 694 701
16. A. Kyrgidis, K.A. Toulis Denosumab-related osteonecrosis of the jaws Osteoporos Int 22 2011 369 370
17. F. Saad, J.E. Brown, C. Van Poznak, T. Ibrahim, S.M. Stemmer, A.T. Stopeck Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann Oncol 23 2011 1341 1347
18. T. Mavrokokki, A. Cheng, B. Stein, A. Goss Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 2007 415 423
19. H. Hsu, D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, E. Timms Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci U S A 96 1999 3540 3545
20. N. Takahashi, N. Udagawa, T. Suda A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function Biochem Biophys Res Commun 256 1999 449 455
21. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
22. T.L. Burgess, Y. Qian, S. Kaufman, B.D. Ring, G. Van, C. Capparelli The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J Cell Biol 145 1999 527 538
23. D.L. Lacey, H.L. Tan, J. Lu, Kaufman, G. Van, W. Qiu Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 2000 435 448
24. N.O. Vidal, H. Brändström, K.B. Jonsson, C. Ohlsson Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids J Endocrinol 159 1998 191 195
25. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Lüthy Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
26. E.A. O'Brien, J.H. Williams, M.J. Marshall Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria Biochem Biophys Res Commun 274 2000 281 290
27. L. Mosekilde, C.H. Sogaard, C.C. Danielsen, O. Torring The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84) Endocrionology 129 1991 421 428
28. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1998 1260 1268
29. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P.T. Leese, C.R. Dunstan The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 2001 348 360
30. P.J. Kostenuik Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength Curr Opin Pharmacol 5 2005 618 625
31. K. Yonemori, Y. Fujiwara, H. Minami, K. Kitagawa, H. Fujii, T. Arai Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases Cancer Sci 99 2008 1237 1242
32. P.J. Kostenuik, H.Q. Nguyen, J. McCabe, K.S. Warmington, C. Kurahara, N. Sun Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J Bone Miner Res 24 2009 182 195
33. Q. Jin, J.A. Cirelli, C.H. Park, J.V. Sugai, M. Taba, P.J. Kostenuik, W.V. Giannobile RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis J Periodontol 78 2007 1300 1308
34. K.H. Taylor, L.S. Middlefell, K.D. Mizen Osteonecrosis of the jaws induced by anti-RANK ligand therapy Br J Oral Maxillofac Surg 48 2010 221 223
35. T.L. Aghaloo, A.L. Felsenfeld, S. Tetradis Osteonecrosis of the jaw in a patient on denosumab J Oral Maxillofac Surg 68 2010 959 963
36. D.D. Marathe, A. Marathe, D.E. Mager Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women Biopharm Drug Dispos 32 2011 471 481
37. T. Van den Wyngaert, K. Wouters, M.T. Huizing, J.B. Vermorken RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19 2011 2035 2040